CEO, Jamie Platt highlights an important shift in diagnostics moving from pandemic-driven urgency to technologies that deliver lasting, real-world clinical and research impact. Targeted proteomics will play a critical role in advancing the next generation of diagnostics and precision medicine.
Learn More
Pictor-affiliated research demonstrating a targeted biomarker assay that enables earlier detection of Johne’s disease by identifying MAP-specific antibodies, with performance comparable to IFN-γ testing. The approach outperforms traditional antibody-based assays and offers a practical, high-throughput solution for improved herd-level disease detection and management.
Learn More
Our comprehensive study on detection of M. bovis infections in cattle using our novel proteomics platform has been published in Frontiers in Veterinary Science (2025; DOI: 10.3389/fvets.2025.1664919). The study details a multiplex design that, versus the IDvet comparator, achieved 100% positive percent agreement, 98.4% negative percent agreement, and 98.9% overall agreement.
Learn More
Pictor-affiliated research on Johne’s disease has been accepted as an in-press, Journal Pre-proof in Tuberculosis (2025; Article 102679; DOI: 10.1016/j.tube.2025.102679). The study compares milk- vs. serum-based antibody tests used across New Zealand dairy herds, giving vets and farmers practical guidance on choosing the right sample type for easier, faster herd screening. Note: this paper evaluates widely used commercial ELISA kits and does not include data from Pictor’s PictArray MAP test, but it supports the sample-efficient testing approaches our platform enables.
Learn More
Get in touch with us to discuss partnerships, investment opportunities, or learn more about our platform.
For support, requests or inquiries info@PictorDx.com
